Related Experiment Video
Updated: Jan 7, 2026
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biomarkers
Richard Camicioli1, Sandra E Black2, Michael J Borrie3,4
1University of Alberta, Edmonton, AB, Canada.
Background:
Mild Cognitive Impairment (MCI) may be caused by mixed pathologies. Blood markers indicative of Alzheimer pathology or neurodegeneration have not been extensively explored in patients with MCI who have features of Lewy Body disease (LB-MCI) (cognitive fluctuations, parkinsonism, hallucinations, and REM-sleep behavior disorder (RBD)). We compared plasma levels of amyloid beta (Aß), tau, glial-fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) between participants in COMPASS-ND who met criteria for LB-MCI with participant with MCI without these features, healthy controls (HC), and participants with Parkinson's disease (PD) with and without MCI.
Method:
Participants with MCI, HC, and PD were recruited as part of the COMPASS-ND study and underwent assessment of demographic and clinical features. Participants with MCI were classified as LB-MCI based on one or more criteria for LB disease. Plasma biomarkers were determined for amyloid species (Aß 42/40 ratio), tau-181, GFAP, and (NfL using Simoa. Groups were compared using ANOVA with post hoc comparisons. Age and sex adjustment was done in ANCOVA models.
Result:
Among participants with MCI in COMPASS-ND, there were 159 (97 M/62 F) with MCI but without LB features and 105 (46 M/32 F) with one or more of the LB-MCI criteria. There were 161 HC (54 M/107 F), 79 PD (42 M/37 F), and 41 PD-MCI (35 M/7 F). The Aß 42/40 ratio and tau-181 differed between groups, with the LB-MCI group showing a lower Aß 42/40 ratio and higher tau-181 than the other groups. Post hoc comparison indicated that the ratio was lower in LB-MCI than HC, PD, and PD-MCI while tau-181 was higher than HC, PD, and MCI without LB features. GFAP and NfL did not differ across groups. Age and sex adjustment did not alter the main findings.
Conclusion:
In COMPASS-ND, participants with features of LB-MCI showed a biomarker profile suggestive of high Alzheimer co-pathology. Higher tau-181 suggests that these individuals might have a higher pathological burden than the other groups. The influence of other co-pathologies (i.e., vascular) and the influence on outcomes will be examined in this cohort. Future studies should examine for the presence of synuclein pathology across these groups.
Insights
Individuals with Lewy Body Mild Cognitive Impairment (LB-MCI) exhibit elevated tau-181 and reduced amyloid beta (Aß) levels, indicating Alzheimer co-pathology. These blood biomarkers suggest a higher pathological burden in LB-MCI patients.
Area of Science:
- Neurology
- Biochemistry
- Neuroscience
Background:
- Mild Cognitive Impairment (MCI) can stem from mixed pathologies, complicating diagnosis.
- Blood biomarkers for Alzheimer's pathology and neurodegeneration are underexplored in Lewy Body Mild Cognitive Impairment (LB-MCI).
- LB-MCI is characterized by cognitive fluctuations, parkinsonism, hallucinations, and REM-sleep behavior disorder (RBD).
Purpose of the Study:
- To compare plasma biomarker levels in LB-MCI patients versus those with MCI without LB features, healthy controls (HC), and Parkinson's disease (PD) patients with and without MCI.
- To investigate the presence of Alzheimer's co-pathology in LB-MCI using blood markers.
Main Methods:
- Plasma levels of amyloid beta (Aß) 42/40 ratio, tau-181, GFAP, and NfL were measured using Simoa in participants of the COMPASS-ND study.
- MCI participants were classified as LB-MCI based on established criteria.
- Statistical comparisons (ANOVA, ANCOVA) were performed across groups, adjusting for age and sex.
Main Results:
- The LB-MCI group showed a significantly lower Aß 42/40 ratio and higher tau-181 compared to HC, PD, and MCI without LB features.
- Plasma GFAP and NfL levels did not significantly differ across the studied groups.
- Age and sex adjustments did not alter these primary findings.
Conclusions:
- LB-MCI patients exhibit a plasma biomarker profile suggestive of concurrent Alzheimer's co-pathology.
- Elevated tau-181 in LB-MCI indicates a potentially higher pathological brain burden.
- Further research is needed to explore other co-pathologies and synuclein pathology in these patient groups.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...